OBJECTIVE: To determine whether expression of the epidermal growth factor receptor (EGFR) is of prognostic value in uveal melanoma. METHODS: Thirty consecutive patients treated for primary posterior uveal melanoma by enucleation or local resection were studied. Tumors were examined for EGFR and CD68 expression by immunohistochemistry on formalin-fixed, paraffin-embedded sections. Extracted DNA from paired frozen tumor and blood samples was examined for loss of heterozygosity on chromosome 3 using polymerase chain reaction-based microsatellite analysis. Immunoreactivity for EGFR was correlated with clinicopathological, chromosome 3, and follow-up data. RESULTS: Immunoreactivity for EGFR was observed in 7 (23%) of 30 uveal melanomas, but was restricted to solitary or small groups of cells with macrophage-like morphology. Immunoreactive cells were confirmed as macrophages using an antibody to the macrophage marker CD68. Chromosome 3 loss, epithelioid cells, and microvascular loops were detected in 17 (57%), 22 (73%) and 19 (63%) of the 30 tumors, respectively. Metastatic disease was detected in 5 patients (17%). No correlation was found between any of these variables and EGFR positivity. CONCLUSIONS: The absence of EGFR immunoreactivity in tumor cells does not support the use of EGFR expression as a prognostic indicator in patients with uveal melanoma. Future EGFR studies in uveal melanoma should be interpreted with caution in view of our findings that tumor-associated macrophages can express this receptor.
OBJECTIVE: To determine whether expression of the epidermal growth factor receptor (EGFR) is of prognostic value in uveal melanoma. METHODS: Thirty consecutive patients treated for primary posterior uveal melanoma by enucleation or local resection were studied. Tumors were examined for EGFR and CD68 expression by immunohistochemistry on formalin-fixed, paraffin-embedded sections. Extracted DNA from paired frozen tumor and blood samples was examined for loss of heterozygosity on chromosome 3 using polymerase chain reaction-based microsatellite analysis. Immunoreactivity for EGFR was correlated with clinicopathological, chromosome 3, and follow-up data. RESULTS: Immunoreactivity for EGFR was observed in 7 (23%) of 30 uveal melanomas, but was restricted to solitary or small groups of cells with macrophage-like morphology. Immunoreactive cells were confirmed as macrophages using an antibody to the macrophage marker CD68. Chromosome 3 loss, epithelioid cells, and microvascular loops were detected in 17 (57%), 22 (73%) and 19 (63%) of the 30 tumors, respectively. Metastatic disease was detected in 5 patients (17%). No correlation was found between any of these variables and EGFR positivity. CONCLUSIONS: The absence of EGFR immunoreactivity in tumor cells does not support the use of EGFR expression as a prognostic indicator in patients with uveal melanoma. Future EGFR studies in uveal melanoma should be interpreted with caution in view of our findings that tumor-associated macrophages can express this receptor.
Authors: Ning Lu; Lihong Wang; Hailong Cao; Liping Liu; Luc Van Kaer; Mary K Washington; Michael J Rosen; Philip E Dubé; Keith T Wilson; Xiubao Ren; Xishan Hao; D Brent Polk; Fang Yan Journal: J Immunol Date: 2014-01-03 Impact factor: 5.422
Authors: Dana M Hardbower; Kshipra Singh; Mohammad Asim; Thomas G Verriere; Danyvid Olivares-Villagómez; Daniel P Barry; Margaret M Allaman; M Kay Washington; Richard M Peek; M Blanca Piazuelo; Keith T Wilson Journal: J Clin Invest Date: 2016-08-02 Impact factor: 14.808
Authors: Francisco Llavero; Miriam Luque Montoro; Alazne Arrazola Sastre; David Fernández-Moreno; Hadriano M Lacerda; Luis A Parada; Alejandro Lucia; José L Zugaza Journal: J Biol Chem Date: 2019-01-15 Impact factor: 5.157
Authors: Laurel A Grisanti; Ashley A Repas; Jennifer A Talarico; Jessica I Gold; Rhonda L Carter; Walter J Koch; Douglas G Tilley Journal: Am J Physiol Heart Circ Physiol Date: 2014-12-05 Impact factor: 4.733
Authors: Patricia O Prada; Eduardo R Ropelle; Rosa H Mourão; Claudio T de Souza; Jose R Pauli; Dennys E Cintra; André Schenka; Silvana A Rocco; Roberto Rittner; Kleber G Franchini; José Vassallo; Lício A Velloso; José B Carvalheira; Mario J A Saad Journal: Diabetes Date: 2009-08-20 Impact factor: 9.461